185 related articles for article (PubMed ID: 25573078)
21. Radiosensitizing effect of galunisertib, a TGF-ß receptor I inhibitor, on head and neck squamous cell carcinoma in vitro.
Jank BJ; Lenz T; Haas M; Kadletz-Wanke L; Campion NJ; Schnoell J; Heiduschka G; Macfelda K
Invest New Drugs; 2022 Jun; 40(3):478-486. PubMed ID: 34985593
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
Medicherla S; Li L; Ma JY; Kapoun AM; Gaspar NJ; Liu YW; Mangadu R; O'Young G; Protter AA; Schreiner GF; Wong DH; Higgins LS
Anticancer Res; 2007; 27(6B):4149-57. PubMed ID: 18229422
[TBL] [Abstract][Full Text] [Related]
23. Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression.
Song B; Park SH; Zhao JC; Fong KW; Li S; Lee Y; Yang YA; Sridhar S; Lu X; Abdulkadir SA; Vessella RL; Morrissey C; Kuzel TM; Catalona W; Yang X; Yu J
J Clin Invest; 2019 Feb; 129(2):569-582. PubMed ID: 30511964
[TBL] [Abstract][Full Text] [Related]
24. Galunisertib inhibits glioma vasculogenic mimicry formation induced by astrocytes.
Zhang C; Chen W; Zhang X; Huang B; Chen A; He Y; Wang J; Li X
Sci Rep; 2016 Mar; 6():23056. PubMed ID: 26976322
[TBL] [Abstract][Full Text] [Related]
25. A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Kelley RK; Gane E; Assenat E; Siebler J; Galle PR; Merle P; Hourmand IO; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Faivre S; Benhadji KA; Giannelli G
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00056. PubMed ID: 31295152
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of NKG2DLs by TGF-β in human lung cancer cells.
Lee YS; Choi H; Cho HR; Son WC; Park YS; Kang CD; Bae J
BMC Immunol; 2021 Jul; 22(1):44. PubMed ID: 34253166
[TBL] [Abstract][Full Text] [Related]
27. Blocking transforming growth factor-β signaling pathway augments antitumor effect of adoptive NK-92 cell therapy.
Yang B; Liu H; Shi W; Wang Z; Sun S; Zhang G; Hu Y; Liu T; Jiao S
Int Immunopharmacol; 2013 Oct; 17(2):198-204. PubMed ID: 23806302
[TBL] [Abstract][Full Text] [Related]
28. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Capper D; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Lahn MM; Wick W
Neuro Oncol; 2016 Aug; 18(8):1146-56. PubMed ID: 26902851
[TBL] [Abstract][Full Text] [Related]
29. A TGFβ Signaling Inhibitor, SB431542, Inhibits Reovirus-mediated Lysis of Human Hepatocellular Carcinoma Cells in a TGFβ-independent Manner.
Ishigami I; Shuwari N; Kaminade T; Mizuguchi H; Sakurai F
Anticancer Res; 2021 May; 41(5):2431-2440. PubMed ID: 33952468
[TBL] [Abstract][Full Text] [Related]
30. Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma.
Giannelli G; Villa E; Lahn M
Cancer Res; 2014 Apr; 74(7):1890-4. PubMed ID: 24638984
[TBL] [Abstract][Full Text] [Related]
31. Galunisertib attenuates progression of trauma-induced heterotopic ossification via blockage of Smad2/3 signaling in mice.
Mao D; Mi J; Pan X; Zhao G; Rui Y
Eur J Pharmacol; 2022 Aug; 928():175109. PubMed ID: 35738451
[TBL] [Abstract][Full Text] [Related]
32. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.
Tran TT; Uhl M; Ma JY; Janssen L; Sriram V; Aulwurm S; Kerr I; Lam A; Webb HK; Kapoun AM; Kizer DE; McEnroe G; Hart B; Axon J; Murphy A; Chakravarty S; Dugar S; Protter AA; Higgins LS; Wick W; Weller M; Wong DH
Neuro Oncol; 2007 Jul; 9(3):259-70. PubMed ID: 17522330
[TBL] [Abstract][Full Text] [Related]
33. Blockade of the TGF-β pathway by galunisertib inhibits the glial-mesenchymal transition in Müller glial cells.
da Silva RA; Roda VMP; Akamine PS; da Silva DS; Siqueira PV; Matsuda M; Hamassaki DE
Exp Eye Res; 2023 Jan; 226():109336. PubMed ID: 36455675
[TBL] [Abstract][Full Text] [Related]
34. Benzalkonium chloride induces subconjunctival fibrosis through the COX-2-modulated activation of a TGF-β1/Smad3 signaling pathway.
Huang C; Wang H; Pan J; Zhou D; Chen W; Li W; Chen Y; Liu Z
Invest Ophthalmol Vis Sci; 2014 Nov; 55(12):8111-22. PubMed ID: 25406285
[TBL] [Abstract][Full Text] [Related]
35. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition.
Peng SB; Yan L; Xia X; Watkins SA; Brooks HB; Beight D; Herron DK; Jones ML; Lampe JW; McMillen WT; Mort N; Sawyer JS; Yingling JM
Biochemistry; 2005 Feb; 44(7):2293-304. PubMed ID: 15709742
[TBL] [Abstract][Full Text] [Related]
36. Galunisertib Exerts Antifibrotic Effects on TGF-β-Induced Fibroproliferative Dermal Fibroblasts.
Peterson JM; Jay JW; Wang Y; Joglar AA; Prasai A; Palackic A; Wolf SE; El Ayadi A
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743131
[TBL] [Abstract][Full Text] [Related]
37. Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis.
Luangmonkong T; Suriguga S; Bigaeva E; Boersema M; Oosterhuis D; de Jong KP; Schuppan D; Mutsaers HAM; Olinga P
Br J Pharmacol; 2017 Sep; 174(18):3107-3117. PubMed ID: 28691737
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
[TBL] [Abstract][Full Text] [Related]
39. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
40. LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer.
Zhang Q; Hou X; Evans BJ; VanBlaricom JL; Weroha SJ; Cliby WA
Cancers (Basel); 2018 Aug; 10(8):. PubMed ID: 30087253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
